← Back to Clinical Trials
Recruiting Phase 2 NCT07064707

NCT07064707 Rupatadine in Patients With Ulcerative Colitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07064707
Status Recruiting
Phase Phase 2
Sponsor Alexandria University
Condition Ulcerative Colitis
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-07-15
Primary Completion 2026-07-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
MesalamineRupatadine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 60 participants in total. It began in 2025-07-15 with a primary completion date of 2026-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression

Eligibility Criteria

Inclusion criteria: * Age ≥ 18 years * Both male and female will be included * Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology. Exclusion criteria: * Breast feeding or pregnancy. * Colorectal cancer patients. * Patients with severe UC. * Patients taking rectal or systemic steroids. * Patients taking immunosuppressives or biological therapies. * Addiction to alcohol and / or drugs. * Known allergy to the studied medications.

Contact & Investigator

Central Contact

Reham Elshafiey, PhD

✉ rehamelshafiey@gmail.com

📞 01025465180

Frequently Asked Questions

Who can join the NCT07064707 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07064707 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07064707 currently recruiting?

Yes, NCT07064707 is actively recruiting participants. Contact the research team at rehamelshafiey@gmail.com for enrollment information.

Where is the NCT07064707 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT07064707 clinical trial?

NCT07064707 is sponsored by Alexandria University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology